Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases
Gurtej S. Cheema, Viktor V. Roschke, David M. Hilbert et al. · Arthritis & Rheumatism · 2001
OBJECTIVE: To determine whether serum levels of B lymphocyte stimulator (BLyS) are elevated in patients with systemic immune-based rheumatic diseases and correlate with serum Ig levels and/or autoantibody titers. METHODS: Sera from 185 patients with various systemic immune-based rheumatic diseases (95 with systemic lupus erythematosus [SLE], 67 with rheumatoid arthritis [RA], 23 with other diagnoses) were assayed for BLyS and Ig. In 7 patients who required arthrocentesis of a swollen knee, coincident serum and synovial fluid samples were assayed for BLyS. Medical charts were retrospectively reviewed for elevated autoantibody titers and proteinuria within a 1-month period before or after collection of sera for BLyS and Ig determination. Sera concurrently collected from 48 normal healthy subjects served as controls. RESULTS: Serum BLyS levels were elevated in 38 of 185 patients (21%) and correlated significantly with serum IgG levels. Serum BLyS levels did not correlate with the patients' age, sex, race, or medications, but correlated positively with anti-double-stranded DNA antibody titers among SLE patients and with rheumatoid factor titers among seropositive RA patients. In contrast, serum BLyS levels correlated inversely with nephrotic-range proteinuria among SLE patients. In every case tested, BLyS levels in clinically inflamed synovial fluids were greater than those in simultaneously obtained sera. CONCLUSION: BLyS may be an important factor in driving polyclonal hypergammaglobulinemia and elevated autoantibody titers in patients with systemic immune-based rheumatic diseases. Local production of BLyS in the joints may contribute to joint pathology. Patients with elevated serum BLyS levels may be ideal candidates for therapeutic targeting of BLyS.
Cited by 802 works. doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s
Authors
References
- Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
- BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth
- TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
- BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
- IgG1 plasmacytosis in interleukin 6 transgenic mice.
- Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice
- Identification and Characterization of a Novel Cytokine, THANK, aTNF Homologue That ActivatesApoptosis, Nuclear Factor-κB, and c-Jun NH2-Terminal Kinase
- TALL-1 is a novel member of the TNF family that is down-regulated by mitogens
- Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
- Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.